

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number
WO 2005/092433 A1

(51) International Patent Classification⁷: A61N 1/18, 5/00

(21) International Application Number:
PCT/IE2005/000030

(22) International Filing Date: 24 March 2005 (24.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0406709.6 25 March 2004 (25.03.2004) GB
0411934.3 27 May 2004 (27.05.2004) GB

(71) Applicant (for all designated States except US): UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK [IE/IE]; College Road, Cork (IE).

(72) Inventors; and


(75) Inventors/Applicants (for US only): MORRISSEY, Anthony [IE/IE]; 27 Oakmount, Tower, Blarney, County Cork

(IE). SODEN, Declan [IE/IE]; 1 Foxwood, Pembroke Woods, Passage West, County Cork (IE). O'SULLIVAN, Gerald [IE/IE]; "Cuan Baoi", Ballinveltig, Currahean Road, Bishopstown, County Cork (IE). COLLINS, Christopher [IE/IE]; 49 Abbey Drive, Riverston Abbey, Ashington, Dublin 7 (IE). DUNNE, Colum [IE/IE]; 23 Richview, Castlecomer Road, Kilkenny (IE). PIGGOTT, John [IE/IE]; 236 The Sweepstakes, Ballsbridge, Dublin 4 (IE). PRIOR, Denton [GB/GB]; The Cottage, Peinmore House, Portree, Isle of Skye IV51 9LG (GB). WATSON, Andrew [GB/GB]; 6 Hallin Park, Waternish, Dunvegen, Isle of Skye IV55 8GJ (GB). MCGEEHIN, Peter [GB/GB]; Oakbridge, School Road, Compton, Newbury RG20 6QU (GB).

(74) Agents: O'BRIEN, John, A. et al.; John A. O'Brien & Associates, Third Floor, Duncairn House, 14 Carysfort Avenue, Blackrock, County Dublin (IE).

[Continued on next page]

(54) Title: APPARATUS FOR PROPHYLAXIS OR TREATMENT OF TISSUE



(57) Abstract: Apparatus (20) for carrying out a prophylactic or treatment procedure on tissue comprises a device (21) having a chamber (22) and at least one active element such as an electrode (23) within the chamber (22). The chamber (22) has an opening (26) through which tissue is drawn into the chamber (22). Means for drawing the tissue into the chamber may comprise a vacuum lumen with vacuum orifices (25) in the chamber (22). Treatment such as electroporation may be applied to tissue in the chamber (22).



(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

| | | |
|--|---|---|
| Applicant's or agent's file reference NATI52/C/WO | FOR FURTHER ACTION | |
| | see Form PCT/ISA/220 as well as, where applicable, item 5 below. | |
| International application No. PCT/IE2005/000030 | International filing date (day/month/year) 24/03/2005 | (Earliest) Priority Date (day/month/year) 25/03/2004 |
| Applicant UNIVERSITY COLLEGE CORK – NATIONAL UNIVERSITY . . . | | |

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 7 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

The international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. **Certain claims were found unsearchable** (See Box II).

3. **Unity of invention is lacking** (see Box III).

4. With regard to the **title**,

the text is approved as submitted by the applicant.

the text has been established by this Authority to read as follows:

APPARATUS FOR PROPHYLAXIS OR TREATMENT OF TISSUE

5. With regard to the **abstract**,

the text is approved as submitted by the applicant.

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regard to the **drawings**,

a. the figure of the **drawings** to be published with the abstract is Figure No. 1

as suggested by the applicant.

as selected by this Authority, because the applicant failed to suggest a figure.

as selected by this Authority, because this figure better characterizes the invention.

b. none of the figures is to be published with the abstract.

“An apparatus for use in the prophylaxis or treatment of tissue”

Introduction

5 This invention relates to an apparatus for carrying out a prophylactic or treatment procedure on tissue, and to a method of prophylaxis or treatment of tissue.

10 Cancers or otherwise diseased tissue in or on the inner surface of the hollow viscera, such as the oesophagus or bowel, are generally visually and surgically accessible with a conventional endoscope. Laparoscopy is a surgical technique for accessing body cavities through a small incision, known as a laparotomy, typically through the abdominal wall. The laparoscope is a type of endoscope with various surgical tools and adaptors, with a diameter of ~10mm and length of ~300mm, shorter than the flexible devices required for the hollow viscera. The laparoscope allows access to 15 organs in the abdomen, including the bowel, liver, stomach, pancreas, spleen and ovaries. The laparoscope can also be used in the chest, when it is known as a thoracoscope, allowing access to the lungs. The same principle applies to bladder and prostate which are accessible through a rigid endoscope, when it is known as a ureteroscope, albeit with different (smaller) dimensions.

20 In the more advanced western economies cancers in the organs accessible with these devices represent the greater fraction of cancers commonly encountered. Furthermore, the use of endoscopic techniques in surgery is increasing because they are minimally invasive, safer and reduce significantly the in-hospital treatment and 25 recuperation periods.

30 Surgical treatment strategies for cancers often include a follow-up period of chemotherapy, although sometimes chemotherapy is the only method used. The term chemotherapy is here used in the most generic sense, and is taken to include the use of medicines, medicinal products, therapeutic agents and other chemical species as in, for example and not limited to, gene therapy and the various sub-classes of this

therapy. Techniques are employed that improve the efficacy of chemotherapy by essentially physical means. These include photo-dynamic therapy (PDT), when a drug is activated or enhanced in effect by the absorption of light, sonophoresis, acoustic or ultrasonic fields and by the application of a uniform or pulsed electric field so that a medicinal product – typically of genetic material that does not easily enter tumour cells – is encouraged to enter cells by the temporary breakdown of cell walls. Therapeutic “electroporation” involves application of electric fields to target cells/tissues, thereby rendering their cell membranes transiently porous, thus making feasible the cellular uptake and efficacy of previously impermeant and ineffective therapeutic agents. Electroporation is a physiological phenomenon that occurs in cell membranes as cells are exposed to electrical fields of sufficiently high intensity. Under such conditions, a high trans-membrane voltage is induced causing changes in the membrane and resulting in enhanced cell membrane permeability. Molecules, such as some drugs or nucleic acids, which are otherwise unable to cross the cell membrane, due to electroporation, can enter the cells. Electroporation is the basis for electrochemotherapy and electogenetherapy. In these combined therapies, the electrically-induced cell membrane permeabilization is exploited to deliver anticancer drugs (electrochemotherapy) or genes (electogenetherapy) directly into the cells. Molecules with intrinsically high activity, such as some anticancer drugs or DNA/RNA molecules, enter the cells in sufficiently large quantities to effectively influence targets within the cells. Radiation therapy is a physico-chemical technique that can be used alone or in conjunction with a chemical agent that acts, for example, as a selective absorber or to activate a precursor to an efficacious substance created in-situ. These techniques can also be used in combination, an illustrative example being ultrasonic enhancement of an applied pulsed electric field. Other combinations are possible and need not be limited to two impressed fields.

In the case of PDT the tissue or tumour is illuminated with radiation in or close to the visible spectrum and the tumour or tissue need not necessarily be contacted by the means of radiation transmission but if direct contact is not achieved the light intensity can still be tailored precisely by the use of both refractive and reflective

rigid elements. In the case of the other physical enhancement methods the tumour or tissue is generally brought into physical contact or close proximity with rigid elements that are typically metallic conductors or radiation sources that are generally solids though not necessarily metallic. Radiation sources can be considered to be active in a sense analogous to electrodes or transmissive elements used for the other enhancement methods. The elements in contact or close proximity with the tissue that bring about the enhancement of the treatment process – whether electrodes, optical elements or radiation sources – are hereafter described by the term ‘active elements’. These active elements can be impregnated with therapeutic agents that are given up to the tissue when in contact with it. This transfer can be further enhanced by the application of a physical enhancement process, or more than one such process in combination.

With most of these physically-based enhancement techniques, difficulties frequently arise in endoscopic implementations. Absence of uniformity in the physical field being applied often occurs which causes variations in the degree of treatment given to different regions of the diseased or cancerous tissue, typically some regions being over-treated and other regions being under-treated.

This invention is therefore aimed at addressing at least some of the difficulties of conventional approaches.

Statements of Invention

According to the invention there is provided apparatus for carrying out a prophylactic or treatment procedure on tissue comprising:

a device having a chamber and at least one active element within the chamber;

means for drawing tissue into the chamber; and

means for applying a treatment to tissue drawn into the chamber.

5 In one embodiment the chamber has an opening through which tissue is drawn into the chamber. The opening may be at a side of the chamber. The opening may be at an end of the chamber.

10 In one case the means for drawing tissue into the chamber comprises means for applying a vacuum to tissue. The apparatus may comprise a vacuum lumen for connecting the chamber in communication with a vacuum source. The apparatus may comprise one or more vacuum orifices for connecting the vacuum lumen in communication with the chamber.

15 In one embodiment the vacuum source is configured to be located externally of a body.

In one case the longitudinal axis of the vacuum lumen is offset radially from the longitudinal axis of the chamber.

20 In one embodiment the means for drawing tissue into the chamber is configured to draw tissue towards the active element. The means for drawing tissue into the chamber may be configured to draw tissue into contact with the active element.

25 In one embodiment the device is configured to define a smooth crossing profile. A distal end of the device may be substantially rounded.

In one case the active element comprises an electrode. The means for applying treatment may comprise means for applying electroporation to tissue in the chamber.

30 In one embodiment the active element comprises a conductive element.

The active element may comprise an optical element.

Alternatively or additionally the active element comprises a radiation source.

5 The active element may alternatively or additionally comprise an ultrasound source.

In one case the apparatus comprises at least two active elements. At least some of the active elements may be the same.

10 At least some of the active elements may be different.

In one embodiment at least one active element has a therapeutic agent associated therewith. For example, the active element may be impregnated with a therapeutic agent.

15

In one arrangement the location of the active elements in the chamber is configured to minimise the variation in intensity of the physical field within the chamber.

In one embodiment the chamber comprises a plurality of openings.

20

In one embodiment the device has means for receiving a treatment device such as an injector, needle or the like.

25

The apparatus may comprise at least one sensor. The sensor may be used to monitor the treatment procedure. The sensor may be provided integral with the active element.

In one embodiment the device has at least one port to facilitate coupling of one or more ancillary devices such as laparoscopic devices to the device.

30

The port may be configured to facilitate coupling of the ancillary laparoscopic device to the device with the ancillary device being optionally aligned with the chamber.

5 In one case the ancillary device comprises an endoscope for transmitting visual information, and/or a needle for injecting a therapeutic agent into tissue.

In one embodiment the device is adapted for mounting to an instrument. The device may be adapted for mounting to a distal end of an instrument. The instrument may comprise an endoscope, a laparoscope, a thoracoscope or a ureteroscope.

10

The instrument may comprise a catheter.

15

In one embodiment the apparatus comprises a connector lumen for connecting the active element and/or the sensor in communication with a controller. The controller may be configured to be located externally of a body.

The invention also provides an instrument, an endoscope, a laparoscope, a thoracoscope, a ureteroscope, or a catheter comprising an apparatus of the invention.

20

In another aspect the invention provides a method of prophylaxis or treatment of tissue comprising the steps of:

providing a device having a chamber and at least one active element within the chamber;

25

delivering the device to a site of interest;

drawing tissue into the chamber;

30

applying treatment to the tissue drawn into the chamber using the at least one active element within the chamber;

releasing the tissue from the chamber; and

5

withdrawing the device.

In one embodiment the tissue is drawn into the chamber by applying a vacuum.

10 The tissue may be drawn towards the active element. The tissue may be drawn into contact with the active element.

In one embodiment the method comprises the step of applying a stimulus to the tissue using the active element.

15

In one case the method comprises the step of applying electrical energy to the tissue.

Alternatively or additionally the method comprises the step of applying electromagnetic energy to the tissue.

20

The method may comprise the step of applying nuclear energy to the tissue.

The method may comprise the step of applying heat energy via microwave or alternative energy source to the tissue.

25

In one case the active element comprises a conductive element. The active element may comprise an electrode and/or an optical element.

In one embodiment the active element comprises a radiation source.

30

The active element may comprise an ultrasound source.

In one embodiment the active element comprises an electrode and the treatment applied to the tissue is an electroporation treatment.

5 In one case the tissue is a diseased tissue such as a tumour. The tumour may be oesophageal, colon, bladder, stomach, kidney, liver, pancreatic, fibrosarcoma, breast, prostate, glioma, lung, rectal, spleen, ovary, or melanoma type.

Alternatively the tissue is a healthy tissue.

10 In one embodiment the method comprises the step of carrying out a further procedure on the tissue. The further procedure may be carried out before drawing tissue into the chamber. Alternatively or additionally the further procedure is carried out after drawing tissue into the chamber.

15 The further procedure may be a treatment procedure and/or a visualisation procedure, and/or a drug treatment procedure, and/or a diagnostic procedure.

20 In one embodiment the method comprises the step of coupling one or more ancillary devices such as laparoscopic to the device.

The method may comprise the step of injecting a therapeutic agent into the tissue.

25 In one embodiment the device is mounted to or mountable to an instrument. The instrument may be an endoscope, laparoscope, thoracoscope, or ureteroscope. The instrument may comprise a catheter.

The device may be mounted to or mountable to a distal end of an instrument.

30 In one embodiment the method comprises the step of monitoring the treatment procedure using a sensor.

In another embodiment the method comprises the step of controlling the treatment procedure using a controller.

5 The site of interest may be a site on an external surface of a body. Alternatively the site of interest is an internal site within a body.

The device of the invention facilitates the endoscopic delivery of therapeutic agents to both normal and tumour tissue. The use of plate electrodes within the chamber 10 allows for a homogenous electric field to be generated during the delivery of the electrical pulses. A defined volume of tissue is drawn within the chamber and safely held in place while the tissue is treated. This invention therefore allows for a defined volume of intraluminal tissue to be treated whether with electrical pulses or an alternative physical treatment that allows for the enhanced uptake of genetic or 15 pharmaceutical agents. Since the discovery that electrical pulses could be used to safely enhance the uptake across the cell membrane of both genes and drugs, various electrode arrangements have been designed for use on both external and intraluminal tissue. Essentially the options have been limited to the use of either macro needle or plate electrodes. Clinically these electrodes have been applied to external tissue e.g. 20 basal cell carcinoma and malignant melanoma, however due to the absence of suitable surgical tools for the application of electroporation to intraluminal tissue the technology has been unable to develop in this area. In the apparatus and method of the invention the volume of tissue being treated is treated to the optimal extent and as uniformly as possible. The effect of having the electrodes contained within a 25 chamber is to allow the surgeon to have precise control of the tissue area being treated, in addition the risk of current leakage or damage to healthy tissue is minimised (as compared to the application with needle based electrodes) due to the electrodes being contained within the device chamber and the target tissue being held in place until the end of the procedure via the use of a vacuum suction.

Having the electrodes housed inside a tissue chamber allows tissue of known proportions (constraints imposed by the chamber size) to be drawn into that chamber. Once the tissue is in the chamber the tissue can be electrically tested via the electrodes or other incorporated sensors such as temperature sensors and with the resulting information the entrapped tissue can be evenly and efficiently electrically treated to provide the best effect or desired effect. This is possible due to the fixed known volume and characteristics such as electrode spacing within the chamber and size of the tissue chamber.

10 Entrapment of the target tissue within the chamber ensures that treatment is limited to that target tissue.

15 Drug treatment injected into the target tissue while the target tissue is held within the tissue chamber and hence between active devices such as electrodes ensures that the drug treated area is the electrically treated area.

20 Holding the target tissue within the chamber by reduced pressure during the injection of the treatment drug will aid the dispersal of that drug throughout the cellular free space prior to electrically treating the tissue. The cellular free space is the desired location of the treatment drug prior to electrically treating the target tissue.

25 The device of the invention can be provided on catheter, endoscope, laparoscope, thoracoscope, or ureteroscope to treat diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs.

30 The invention provides the application of vacuum pressure to help disperse any diagnostic, therapeutic, indicative, investigational solution within diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs. The vacuum suction may be applied through a manifold.

It will be appreciated that the volume of chamber can be altered at design/manufacture stage, to suit the application.

5 The device of the invention could be used for all known tumour types accessible both internally and extra-dermal, including but not limited to: oesophageal, colon, bladder, stomach, kidney, liver, pancreatic, fibrosarcoma, breast, prostate, glioma, lung, rectal, spleen, ovary, and melanoma.

10 The device facilitates delivery of drugs and/or gene therapies to target sites within the diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs. Thus the invention provides a minimally invasive device for the site specific delivery of both drugs and/or gene therapies to target sites within diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs.

15 The device may be used for the treatment of localised and defined volumes of diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organ.

20 The invention provides an endoscope, laparoscope, thoracoscope, or ureteroscope catheter borne device designed specifically to deliver electrical pulses, nanoparticles, polymers, ultrasonic sound waves, microwaves, gene therapies, chemotherapies, and drugs.

25 The device may be used to deliver repeated follow up treatments via a minimally invasive protocol.

30 The device has conducting materials mounted in or on its walls and/or the chamber may be fitted with conducting materials. Such conducting materials allow for delivery of electrical pulses to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs by employing the conducting material as electrodes.

In the case of metallic materials they can be any suitable biocompatible material, including but not limited to gold, platinum, and/or stainless steel.

5 The electrodes can be planar rigid electrodes, block electrodes, mesh electrodes, they may be manufactured by thin film deposition of metal on various substrates including but not limited to silicon, plastic, polymer, ceramic and the like.

10 The electrodes can be silicon or polymeric needle based electrodes of various dimensions, or arrays of same. Needles can be fabricated by machining. Needles or microneedles can be fabricated in silicon by Potassium Hydroxide (KOH) etching or by deep reactive ion etching (DRIE) etching. Needles or microneedles can be fabricated from polymers by methods including but not limited to polymer hot embossing.

15 The electrodes could be flexible electrodes and/or substances or substrates capable of conducting electrical pulses.

20 The chamber can include any number or arrangement or location of electrodes as required. Electrode arrangements can include any or all combinations of the above types of electrodes / conducting materials / conducting mechanisms.

25 The invention facilitates delivery of electrical pulses to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs by employing electrodes or other conducting materials, as outlined above, capable of conducting/delivering nanoparticles, polymers, ultrasonic sound waves, microwaves, gene therapies, chemotherapies, and/or drugs. The invention also facilitates delivery of electrical pulses to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs by employing electrodes or other conducting materials, 30 as outlined above.

The device may be engineered to improve the delivery of gene and drug products and any diagnostic, therapeutic, indicative, investigational solution by enhancing their transport across the cell membrane.

5 The invention provides electroporation pulse delivery combined with localised delivery of a therapeutic agent via a septum or channel or port.

In one embodiment, the electrodes / conducting materials / mechanism on the device / chamber walls can accommodate such therapeutic agent delivery channels / routes. 10 These delivery routes can be channels, microchannels, capillary channels, pores, holes, ports, needles, microfluidic channels, macrofluidic channels or the like.

15 A separate injection / microinjection needle which can extend into the chamber once (or before) the tissue / organ area being treated is in the chamber to facilitate injection of a therapeutic agent.

20 The device of the invention is capable of enhancing the delivery of genes and drugs and any diagnostic, therapeutic, indicative, investigational solution across the cell membrane via a minimally invasive procedure using either endoscopic, laparoscopic, thoracoscopic, or ureterscopic catheter borne devices.

25 The device may be used to assist in the down-staging of tumour volume prior to surgery or other treatment. More particularly, the device may be used to assist in the down-staging of tumour volume before surgery or other treatment by delivering electrical pulses via an endoscope, laparoscope, thoracoscope, or ureteroscope catheter combined with injecting a drug or any diagnostic, therapeutic, indicative, investigational solution to the tumour tissue.

30 The device may be used to assist in the down-staging of tumour volume before surgery or other treatment by delivering nanoparticles, polymers, ultrasonic sound waves, microwaves, gene therapies, chemotherapies, and drugs via an endoscope,

laparoscope, thoracoscope, or ureteroscope catheter combined with injecting a drug or any diagnostic, therapeutic, indicative, investigational solution to the tumour tissue.

5 Any suitable down-staging technique may be used including heat / delivery of other forms of radiation / energy and the like.

10 The invention facilitates delivery of a homogenous electrical field to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs via laparoscopic or endoscopic means.

15 The invention provides an endoscopic, laparoscopic, thoracoscopic, ureterscopic based device capable of injecting a gene or drug solution or any diagnostic, therapeutic, indicative, investigational solution at specific diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs, and simultaneously providing a real time visual output for monitoring of the procedure.

20 The invention also provides an endoscopic, laparoscopic device capable of injecting a gene or drug solution or any diagnostic, therapeutic, indicative, investigational solution at specific diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs, delivering electrical pulses site specifically to fixed volumes and simultaneously providing a real time visual output for monitoring of the procedure.

25 The invention further provides an endoscopic, laparoscopic device capable of injecting a gene or drug solution or any diagnostic, therapeutic, indicative, investigational solution at specific diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs, delivering electrical pulses specifically to fixed tissue volumes of diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs and simultaneously providing a real time visual output

for monitoring of the procedure, in addition to monitoring of any temperature, pH, permeability, impedance, conductivity changes that may occur during the procedure.

5 The device facilitates delivery of electrical pulses to induce a stress response in diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs.

10 The invention enables delivery of defined electrical pulses to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs causing a loss of cell function in response to environmental stresses, including but not limited to 15 temperature, pH, permeability, impedance, conductivity.

15 The invention also enables delivery of defined electrical pulses to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs causing a disruption across the cell nucleus and altering the ability of the cell to respond to environmental stresses.

20 The invention provides a device to draw diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs within a chamber under vacuum pressure, with the additional characteristics or capabilities of allowing injection of a 25 genetic or drug solution or any diagnostic, therapeutic, indicative, investigational solution specifically to the diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs and for subsequent delivery of electrical pulses to the diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs via conductive electrodes spaced apart on either inner wall of the chamber. Furthermore, the electrodes have been designed to incorporate temperature chips to 30 allow for real time monitoring of the tissue temperature before, during and after delivery of electrical pulses, while the chamber also allows for monitoring via a visual output device. The device may also have the capacity to be altered to allow for its attachment or integration to an endoscope or laparoscope or other suitably engineered device to allow for application of the device to diseased, cancerous,

5 tumourgenic and/or healthy human or animal tissue and/or organs employing as minimally invasive a procedure as possible. The device may be integrated onto a laparoscope, thoracoscope, ureteroscope or endoscope. The device can also be engineered to allow for the delivery of ultrasonic energy to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs. The device can also be engineered to allow for the delivery of microwave energy to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs.

10 In addition the device may be used to deliver nanoparticles site specifically to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs. More particularly, the device may be used to deliver nanoparticles site specifically to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs and for subsequent delivery of electrical pulses to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs via 15 conductive electrodes spaced apart on either inner wall of the chamber.

The invention enables application of electrical pulses, ultrasound and microwave energy to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs.

20 The invention also enables application of electrical pulses and ultrasound to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs to reduce tumour volume.

25 Electrical pulses and microwave energy may be applied to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs to reduce tumour volume via sensitising the cells to heat after electroporation.

30 In one aspect the invention provides a device to draw diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs within a chamber under vacuum pressure, with the additional characteristics or capabilities of allowing

injection of a genetic or drug solution or any diagnostic, therapeutic, indicative, investigational solution specifically to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs and for subsequent delivery of electrical pulses to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs via conductive electrodes spaced apart on either inner wall of the chamber. Furthermore the device is capable of delivering microwave energy to electric pulse-sensitised diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs within the chamber.

10 In another aspect the invention provides a device to draw diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs within a chamber under vacuum pressure, with the additional characteristics or capabilities of allowing injection of a genetic or drug solution or any diagnostic, therapeutic, indicative, investigational solution specifically to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs and for subsequent delivery of nanoparticles, polymers, ultrasonic sound waves, microwaves, gene therapies, chemotherapies, and drugs to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs via conductive electrodes spaced apart on either inner wall of the chamber. Furthermore the device is capable of delivering 15 microwave energy to electric pulse sensitised diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs within the chamber.

20 The invention also provides a device to draw diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs within a chamber under vacuum pressure, with the additional characteristics or capabilities of allowing injection of a genetic or drug solution or any diagnostic, therapeutic, indicative, investigational solution specifically to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs and for subsequent delivery of nanoparticles, polymers, ultrasonic sound waves, microwaves, gene therapies, chemotherapies, and drugs to 25 diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs via conductive electrodes spaced apart on either inner wall of the chamber.

30

Furthermore the device is capable of delivering nanoparticles, polymers, ultrasonic sound waves, microwaves, gene therapies, chemotherapies, and drugs to diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs sensitised to nanoparticles, polymers, ultrasonic sound waves, microwaves, gene therapies, chemotherapies, and drugs within the chamber.

5 A device can draw diseased, cancerous, tumourgenic and/or healthy human or animal tissue and/or organs within a chamber under vacuum pressure and may contain micro needles, typically of silicon, that assist in maintaining the tissue within the chamber.

10

This invention relates to physical treatment of tumours and tissue. In particular, this invention is concerned with the treatment of tumour or otherwise diseased tissue in a region that is localised and of defined volume. The tissue is brought into proximity with the means of treatment typically by implementing the invention as a treatment head in the form of an attachment to a medical device, typically an endoscope or a laparoscope. An important aspect of the invention concerns the enhancement of the efficacy of a therapeutic agent by the application of a physical stimulus and the optimisation of the uniformity of the physical field experienced by the treated volume. A further aspect of the invention is that it can be implemented as a 15 disposable treatment head for use on an individual patient in a single treatment session.

20 In this invention in order to improve the uniformity of the impressed physical field, the treatment volume is regularly defined by the chamber and is imposed upon the otherwise irregularly shaped tissue to be treated by drawing the tissue into the chamber. This has been found to be preferable to a less regularly shaped volume. Through the use of an endoscope visual information allows for relatively precise 25 positioning of the means of treatment. Surprisingly, in this invention, we have found that the improved definition of the treatment volume can be achieved by using vacuum or suction to draw the tissue to be treated into an appropriately shaped cavity 30 with an optimum array of active elements for the process enhancements involved.

5 The use of negative pressure in this way has the added benefit of reducing interstitial pressure than can be elevated in tumour tissue, such a reduction improving the uptake by the tissue of therapeutic agent. The therapeutic agent can be delivered by injection, from an intra-venous drip or it can be injected into the volume of tissue after it has been drawn into the treatment head.

10 In the case where the volume of tumour or tissue to be treated is large relative to the volume treated on each occasion, adjacent volumes of diseased tissue can be treated by indexing the treatment volume over the diseased volume. The visualisation provided by the endoscope allows this to be achieved relatively precisely. Furthermore the processes involved generate physical changes such as increase in temperature, and it is useful to follow the processes using appropriate sensing means, such as a temperature sensor.

15 Brief Description of the Drawings

The invention will be more clearly understood from the following description of some embodiments thereof, given by way of example only, with reference to the accompanying drawings, in which: -

20

Fig. 1 is a perspective view of an apparatus for carrying out a prophylactic or treatment procedure on tissue according to the invention;

25

Fig. 2 is a side view of the apparatus of Fig. 1;

Fig. 3 is an end view of the apparatus of Fig. 1;

Fig. 4 is a perspective view of the component parts of the apparatus of Fig. 1;

30

Fig. 5 is a perspective view of the component parts of Fig. 4 assembled to form the apparatus of Fig. 1;

Fig. 6 shows a general view of one embodiment of the invention;

5 Fig. 7 illustrates details of the construction of the device by showing orthogonal vertical sections;

Fig. 8 illustrates one means of attaching an embodiment to the end of an endoscope, Fig. 7 shows suction ports but not active elements, while in Fig. 8 both suction ports and active elements are omitted for clarity;

10

Fig. 9 is an elevational view of another device of the invention;

Fig. 10 is a cross-sectional view on the line A-A in Fig. 9;

15

Figs. 11(a) to 11(c) are diagrams illustrating a method of using the apparatus of the invention;

Fig. 12 is a cross-sectional view of a typical laparoscopic port with the device of the invention in place;

20

Fig. 13 is a view of a proximal handle end of the access port;

Fig. 14(a) and 14(b) are perspective views of the device of the invention mounted to the end of a laparoscope;

25

Fig. 15 is a cross-sectional view of a detail of Fig. 14 illustrating the mounting of the device to the endoscope;

30

Fig. 16 is a diagram illustrating the application of the device of the invention to intraluminal oesophageal tissue via an endoscope; and

Fig. 17 is a diagram of an endoscope with the device of the invention.

Detailed Description

5 Referring to the drawings, and initially to Figs. 1 to 5 thereof, there is illustrated an apparatus 20 according to the invention. The apparatus 20 is suitable for carrying out a prophylactic or treatment procedure on tissue.

10 The apparatus 20 comprises a device 21 having a treatment chamber 22 and a plurality of active elements 23 within the chamber 22, and a vacuum lumen 24.

The chamber 22 has a large opening 26 at a side of the chamber 22, through which tissue can be drawn into the chamber 22.

15 The proximal end of the vacuum lumen 24 is connected in communication with a vacuum source located externally of a body, and a distal end of the vacuum lumen 24 is connected in communication with the chamber 22 by means of a plurality of vacuum orifices 25 in the rear wall of the chamber 22.

20 The vacuum lumen 24 may be employed to apply a vacuum to tissue, and in this way to draw tissue into the chamber 22 into contact with the active elements 23.

As illustrated in Fig. 3, the longitudinal axis A-A of the vacuum lumen 24 is offset radially from the longitudinal axis B-B of the chamber 22.

25 In this case each active element 23 is provided in the form of a rigid planar member fixedly attached to the interior wall of the chamber 22. Each active element 23 comprises an electrode for applying an electroporation treatment to tissue drawn into the chamber 22, and an integral sensor for monitoring the treatment procedure.

The location of the active elements 23 within the chamber 22 is chosen to minimise the variation in intensity of the electric field within the chamber 22. In this manner, the device 21 achieves a substantially homogenous physical field throughout the chamber 22.

5

Connecting leads 28 connect the active elements 23 in communication with a controller located externally of a body. To minimise the overall volume of the apparatus 20, the connecting leads 28 extend through the vacuum lumen 24, which acts as a housing around the connecting leads 28.

10

The device 21 has a port 29 to facilitate coupling of one or more ancillary laparoscopic devices to the device 21. As illustrated in Fig. 3, the port 29 is aligned with the chamber 22 so that the ancillary laparoscopic device will be coupled to the device 21 aligned with the chamber 22.

15

Suitable ancillary laparoscopic devices that may be coupled to the device 21 include an endoscope for transmitting visual information in relation to the prophylactic or treatment procedure being performed on tissue, and/or a needle for injecting a therapeutic agent into tissue drawn into the chamber 22.

20

As illustrated in Figs. 2 and 3, the distal end 27 of the device 21 is substantially rounded. In this way the device 21 defines a smooth crossing profile. The device 21 is formed of a moulded body, in this case.

25

The apparatus 20 may be mounted to an instrument for delivery to a site of interest in a body and subsequent retrieval from the body. Typically the apparatus 20 will be mounted to the distal end of the instrument.

30

Suitable instruments to which the apparatus 20 may be mounted include an endoscope, a laparoscope, a thoracoscope, a ureteroscope, a catheter.

In use, the apparatus 20 is mounted to an instrument, and the instrument is advanced through a body to deliver the apparatus 20 to a desired site of interest within the body. A vacuum is then applied using the vacuum source externally of the body. The vacuum is exerted on tissue via the vacuum lumen 24 and the vacuum orifices 5 25 to draw the tissue into the chamber 22 and into contact with the active elements 23.

10 The electrodes in the active elements 23 are used to apply an electroporation treatment to the tissue in the chamber 22. During the treatment procedure, the sensors in the active elements 23 enable the user to monitor the progress of the treatment procedure, and the progress of the treatment procedure may be controlled 15 using the controller.

When the treatment procedure has finished, the vacuum is released to release the 15 tissue from within the chamber 22, and the apparatus 20 is retrieved from the body by withdrawing the instrument.

20 A further procedure may be carried out on the tissue before and/or after drawing tissue into the chamber 22. Possible further procedures include a treatment procedure, a visualisation procedure, a drug treatment procedure, or a diagnostic procedure..

25 The apparatus 20 of the invention is suitable for treating a diseased tissue, such as a tumour. The tumour may be oesophageal, colon, bladder, stomach, kidney, liver, pancreatic, fibrosarcoma, breast, prostate, glioma, lung, rectal, spleen, ovary or melanoma type.

The apparatus 20 of the invention is also suitable for carrying out a prophylactic treatment on healthy tissue.

The site of interest may be an internal site within the body, or an external site on an external surface of the body.

It will be appreciated that the configuration of the device 21 may be altered to suit
5 the requirements of the clinical procedure and/or to suit the requirements of the anatomy of the patient. For example the opening to the chamber may alternatively or additionally be provided at an end of the chamber 22. The chamber may have a plurality of openings.

10 It will also be appreciated that the active elements may be provided in a variety of possible forms. For example the active element may comprise a conductive element, and/or an optical element, and/or a radiation source, and/or an ultrasound source. The active element may apply a physical stimulus, and/or electrical energy, and/or electromagnetic energy, and/or nuclear energy, and/or heat energy to the tissue. The
15 active element may be impregnated with a therapeutic agent.

Each active element within the chamber 22 may be the same. Alternatively two or more of the active elements within the chamber 22 may differ from one another.

20 In Fig. 6 there is illustrated another apparatus according to the invention, which is similar to the apparatus 20 of Figs. 1 to 5.

Fig. 6 shows a body 4 that is moulded or machined and made from biocompatible metal, polymer or ceramic material that is approved for short-term use in the human
25 body. Within the body there is formed a chamber 5, the internal walls of which define a regular cross section into which tissue or tumour is drawn by the application of a vacuum to the chamber 5 via the lumen 2 and multiple orifices 6 connected to the lumen 2 via the internal manifold 8. The vacuum is generated by a suction pump or other means connected to the proximal end of the lumen 2. In the walls of the
30 chamber 5 there are located active element means 7 for impressing onto the tissue drawn into the chamber 5 the physical stimulus, the active elements 7 being arranged

in such a way as to minimise the variation in intensity of the physical field within the chamber 5. Integral within or separate from the active element means 7 are optional sensors for monitoring the progress of the treatment process also located in the walls of the chamber 5. Typically sensors and active elements 7 will be connected to external circuits via connecting wires and/or optical fibres that are conveniently but not necessarily located within the vacuum lumen 2. Where contacting means 7 is employed for the application of an electric field, or other electrical processes, such as RF heating for example, the active elements 7 can be planar, interdigitated or otherwise shaped and can incorporate features appropriate to the scale of the process or processes being employed for enhancement purpose. Sources of ultrasound can also be active elements. Where therapy stimulated by radiation in or adjacent to the visible spectrum is employed contacting means 7 can be tailored precisely by the use of both refractive and reflective rigid elements so as to achieve the required intensity distribution in the treatment volume.

15

The end face of moulded body 4 contains, in addition to the means for attaching lumen 2 mechanical features 1 for registering it with the end face of an endoscopic device 12 so as to form a rigid extension that does not obscure the means integral within the body of the endoscope for transmitting visual information to the proximal end so that the surgeon can observe the processes being carried out at the distal end. In an alternative configuration, the vacuum tube attached to the device is taped to the outside of the body of the endoscope. Any electrical conductors and/or optical fibres that are required, and located for convenience inside the vacuum tube can be separated at the control end of the endoscope leaving one port for the vacuum and others for the electrical and/or optical connections.

25 Figs. 7 and 8 show another embodiment of the invention, in which the mechanical features 1 comprise a hollow peg 10 that fits into the biopsy port of the endoscopic means, and a 'half moon' step 11 machined out of the body 4 of radius similar to that of the body of the endoscopic means, such that when the peg 10 is located within the biopsy port of the endoscope, the body 2 is unable to rotate relative to the endoscopic

body 12, and is thus rigidly fixed in the rotational axis about the peg. Between the body 4 and the peg 10 there can be located a septum that acts to seal the internal parts of the endoscopic means from the applied vacuum, and through which a needle can be inserted via the biopsy channel to act as a further means for contacting the 5 tumour or tissue, and through which a therapeutic agent can be injected into the tumour or tissue. In this case the mild vacuum creates a negative pressure drawing the therapeutic agent into and around the contained surface of the tissue or tumour. In this embodiment the vacuum tube is taped to the outside of the endoscope.

10 Referring to Fig. 9 and Fig. 10 there is illustrated a simplified version of the device of the invention comprising a housing 50 having a tissue receiving chamber 51 with vents 52 leading from the chamber 51 to an underlying reduced pressure manifold 53. Electrodes 54 are in this case positioned in the side walls of the chamber 51. The device also has an injection port 10.

15 One use of the devices of the invention is illustrated in Figs. 11(a) to 11(c). In this case target tissue is indicated by reference 60 and a treatment needle 61 which is passed through an injection septum or valve 62 is also illustrated. As illustrated in Fig. 11(a) the treatment head tissue chamber 51 is offered up to the target tissue 60. 20 The treatment head 50 is cut-away to show the chamber 51, electrode 54, reduced pressure manifold 53 with tissue chamber vents 52 and injection septum 62. Fig. 11(b) illustrates visualisation of the entrapped target tissue 60 after the activation of the vacuum system when the treatment head 50 is applied to the surface of the target tissue 60. While the target tissue 60 is held by the reduced pressure within the tissue 25 chamber 51, the treatment needle 61 (such as for a delivery of a drug) is pushed through the injection septum 62 and into the entrapped tissue 60 [Fig. 11(c)]. The treatment (such as a drug treatment) is applied into the target tissue while the tissue is held under reduced pressure prior to applying the treatment pulse.

30 Fig. 12 illustrates a typical laparoscopic port 70 for use in the invention. The port 70 comprises a cannula 68 which is inserted through the epidermis 71 and subcutaneous

tissues 72 into a body cavity 73. The treatment head 50 is attached to a laparoscopic shaft 24 and the shaft is passed through the port 70 and the cannula 68 into the body cavity 23 to gain access to the internal tissues/organs. A reduced pressure line 78, low dead volume treatment delivery tubing 79 and the electrical input/output wiring pass up through the inside of the shaft 74 to a proximal handle section 69. The proximal handle arrangement 69 is illustrated in Fig. 13. An electrical input/output connector 75 allows connection of the treatment head to a signal generator/analyser. A reduced pressure line 78 emerges from the handle 69 at a port 79 and may then be attached to a vacuum pump. A low dead volume treatment (e.g. drug) delivery tube 79 in this case passes the full length of the handle 64 and emerges at the upper end and may then be attached to a pressurised injection device. The handle arrangement 69 has a thumb operated activator 76 for the injection system and a handle swivel lock nut 80.

A treatment head 50 of the invention attached to a typical endoscope is illustrated in Figs. 14(a) and 14(b). The treatment head 50 is in a form for attachment to an endoscope distal end 84. An injection guide tube 85 from the treatment head 50 is passed up through a biopsy port 86 of the endoscope 83. When the treatment head 50 is seated against the endoscope end 84 using a half moon cut-out 88 on top of the treatment head 50, surgical tape 81 may be used to secure the reduced pressure line 87 to the outside of the endoscope 83. The reduced pressure line 87 also houses the electrical input/output wires from the treatment head 50. Referring especially to Fig. 15 the half moon shaped cut-out 88, once seated against the endoscope distal end 84 prevents the treatment head 50 from swivelling due to the offset positioning of the endoscope biopsy port 86.

Referring to Fig. 16 there is illustrated another application of the invention to intraluminal oesophageal tissue. A treatment head 90 of the invention is provided at a distal end of an instrument (such as an endoscope) shaft 91 and inserted into a squamous oesophagus 92 to access a tumour 93 which in this case is near the stomach 94. A treatment procedure or a number of such procedures as described

herein may be applied to the tumour, when it has been drawn into the treatment chamber.

5 Fig. 17 illustrates the integration of a treatment head 95 of the invention onto the distal end 96 of an endoscope 97. The endoscope 97 has a proximal end with an eyepiece 98 and various ports 99 for wires, instruments and the like. A side section has a flexible shaft 100 for transmission of light, air, water and the like. Typically, a main shaft 10 of the endoscope is flexible.

10 The invention is further described by way of the following examples.

15 One embodiment of the invention is formed from machined nylon in three parts. The cap and body form a hollow cylinder 11 mm in diameter and 35 mm long with a hemispherical shape at the distal end. In the wall of the cylinder the opening for drawing in tissue into the chamber is formed. The cap includes the tubes and other features to connect to the endoscope and for transmitting the physical stimulus to the active elements. The active elements and vacuum connection to the chamber are fabricated as a separate sub-assembly that allows in this case metallic electrodes to be attached to the inner walls of the insert prior to sealing in place within the case 20 and to the top. The volume of the chamber is 5 x 5 x 15 (all dimensions in mm).

25 In a second embodiment a two-part construction is employed. The case and top are formed from one piece of acetyl plastic while the insert and end cap are formed from another piece of acetyl plastic. This arrangement gives a more robust device that is unlikely to separate during use while still allowing initial access to the insert for fitment of the active elements.

30 In both embodiments the alignment of the device is offset from the end of the endoscope and the curve described by the endoscope periphery is cut into the top of the cap to a depth 5mm. In conjunction with a 4.2mm tube that locates into the

biopsy port of the endoscope this locks the body in position and prevents rotation during use.

In one embodiment the vacuum line is made from 4.5mm OD silicon rubber tubing
5 that also acts as the conduit for the connecting wires and is taped to the outside of the endoscope before insertion into a patient. Alternatively 1.9mm OD polyurethane catheter tubing is used which is less intrusive. Kevlar filaments can be included within the vacuum tube as well as cables or optical fibres so as to minimise damage through stretching. A suitable electrical conductor used for some devices is 0.91mm
10 OD coaxial wire (Nexans Filotex). The coaxial wire is first soldered to the edge of the active elements using standard LMP solder prior to being secured to the walls of the chamber.

The vacuum line is secured to a stainless steel tube that is fixed into a 1.2mm hole that runs the length of the acetyl insert. Two or three openings to the vacuum are
15 created in the back wall of the chamber to draw in the tissue. For example 0.3mm holes are drilled through the chamber floor into the 1.2mm diameter conduit. In tests a negative pressure of 0.6 atmospheres is needed to draw tissue into and fill the chamber. The vacuum holes can be profiled so as to minimise the possibility of becoming blocked by tissue if repeat applications are employed on a large volume of
20 tissue or tumour.

Stainless steel electrodes are fixed into the walls of the chamber using 301 EpoTek medical adhesive. This adhesive readily adheres to the electrodes but is less good for bonding acetyl plastic. To overcome this a glue rivet method is employed where 1
25 mm countersunk holes are first drilled through the side-walls of the insert. The electrodes are then held in position and 301 medical adhesive applied until the holes become filled. Once the 301 has cured overnight at room temperature, the taper wedge created holds the electrodes firmly in place. The insert with electrodes is fitted into the outer case and bonded using 301 medical adhesive, the device sealed
30 and the chamber floor coated with Dow Corning 731 silicon rubber. The unit is finished by addition of the vacuum line and an electrical connector. This design and

the method of fabrication is quite flexible, allowing for example variations in the electrode spacing or orifice size.

Alternative methods of manufacturing the treatment chamber include injection moulded as a single piece using a multi-part tool with inserts to incorporate the means of contacting the treatment volume. This method of manufacture would be particularly suited to the implementation as a disposable treatment head for use on an individual patient in a single treatment session.

Units with the following dimensions have been made with multiple electrodes arranged evenly down the side-walls of the chamber and suitable for the application of an electric field to the tissue volume.

- a. 10 mm long opening, 5 mm wide (electrode to electrode) and 5 mm deep;
- b. 10 mm long opening, 4 mm wide gap and 5 mm deep;
- c. 10 mm long opening, 3 mm wide gap and 5 mm deep;
- d. 15 mm long opening, 5 mm wide gap (electrode to electrode) and two temperature sensors mounted on the back wall;
- e. 15 mm long opening, 5 mm wide, one 20 mm electrode on one wall and two 5 mm electrodes on second wall with temperature chip between the two smaller electrodes.

These units are machined in two parts from acetyl rod of 11 mm diameter and then bonded together, tapered glue pins being created during this process. Two or three openings to the vacuum are created in the back wall to draw in the tissue. In tests a negative pressure of 0.6 atmospheres was needed to draw tissue into and fill the chamber.

Another device is of a size required to fit down the treatment channel of the endoscope rather than be fixed onto the end of the endoscope. This device also uses a small vacuum chamber but the treatment area / volume is small, with characteristic

dimensions of 2 mm. The biopsy port connection acts as the port for the injection of therapeutic agent, a septum being fitted into the biopsy port location tube. This has a major advantage in that the site of injection is also exactly the site of the tissue the treatment of which is enhanced. This septum is necessary to eliminate the need to 5 evacuate the whole biopsy port of the endoscope during application of a vacuum.

In a further embodiment the active elements are interdigitated electrodes so as to launch ultrasonic waves into the tissue.

10 In a further embodiment the active elements are electrodes configured so as to launch radio-frequency waves into the tissue.

In a further embodiment the active elements are optical wedges configured at the end of an optical fibre or optical fibres so as to evenly illuminate the tissue.

15 The invention is not limited to the embodiments hereinbefore described, with reference to the accompanying drawings, which may be varied in construction and detail.

Claims

1. Apparatus for carrying out a prophylactic or treatment procedure on tissue comprising:

5

a device having a chamber and at least one active element within the chamber;

10

means for drawing tissue into the chamber; and

means for applying a treatment to tissue drawn into the chamber.

2. Apparatus as claimed in claim 1 wherein the chamber has an opening through which tissue is drawn into the chamber.

15

3. Apparatus as claimed in claim 2 wherein the opening is at a side of the chamber.

20

4. Apparatus as claimed in claim 2 or 3 wherein the opening is at an end of the chamber.

5. Apparatus as claimed in any of claims 1 to 4 wherein the means for drawing tissue into the chamber comprises means for applying a vacuum to tissue.

25

6. Apparatus as claimed in claim 5 wherein the apparatus comprises a vacuum lumen for connecting the chamber in communication with a vacuum source.

30

7. Apparatus as claimed in claim 6 wherein the apparatus comprises one or more vacuum orifices for connecting the vacuum lumen in communication with the chamber.

8. Apparatus as claimed in claim 6 or 7 wherein the vacuum source is configured to be located externally of a body.
9. Apparatus as claimed in any of claims 6 to 8 wherein the longitudinal axis of the vacuum lumen is offset radially from the longitudinal axis of the chamber.
10. Apparatus as claimed in any of claims 1 to 9 wherein the means for drawing tissue into the chamber is configured to draw tissue towards the active element.
11. Apparatus as claimed in claim 10 wherein the means for drawing tissue into the chamber is configured to draw tissue into contact with the active element.
12. Apparatus as claimed in any of claims 1 to 11 wherein the device is configured to define a smooth crossing profile.
13. Apparatus as claimed in claim 12 wherein a distal end of the device is substantially rounded.
14. Apparatus as claimed in any of claims 1 to 13 wherein the active element comprises an electrode.
15. Apparatus as claimed in claim 14 wherein the means for applying treatment comprises means for applying electroporation to tissue in the chamber.
16. Apparatus as claimed in any of claims 1 to 15 wherein the active element comprises a conductive element.
- 30 17. Apparatus as claimed in any of claims 2 to 16 wherein the active element comprises an optical element.

18. Apparatus as claimed in any of claims 1 to 17 wherein the active element comprises a radiation source.
- 5 19. Apparatus as claimed in any of claims 1 to 18 wherein the active element comprises an ultrasound source.
20. Apparatus as claimed in any of claims 1 to 19 wherein the apparatus comprises at least two active elements.
- 10 21. Apparatus as claimed in claim 20 wherein at least some of the active elements are the same.
22. Apparatus as claimed in claim 20 wherein at least some of the active elements are different.
- 15 23. Apparatus as claimed in any of claims 1 to 22 wherein at least one active element has a therapeutic agent associated therewith.
- 20 24. Apparatus as claimed in claim 23 wherein the active element is impregnated with a therapeutic agent.
- 25 25. Apparatus as claimed in any of claims 20 to 24 wherein the location of the active elements in the chamber is configured to minimise the variation in intensity of the physical field within the chamber.
26. Apparatus as claimed in any of claims 1 to 25 wherein the chamber comprises a plurality of openings.
- 30 27. Apparatus as claimed in any of claims 1 to 26 wherein the apparatus comprises at least one sensor.

28. Apparatus as claimed in claim 27 wherein the sensor is used to monitor the treatment procedure.
- 5 29. Apparatus as claimed in claim 27 or 28 wherein the sensor is provided integral with the active element.
- 10 30. Apparatus as claimed in any of claims 1 to 29 wherein the device has at least one port to facilitate coupling of one or more ancillary laparoscopic devices to the device.
- 15 31. Apparatus as claimed in claim 30 wherein the port is configured to facilitate coupling of the ancillary device such as a laparoscopic device to the device with the ancillary device being optionally aligned with the chamber.
- 20 32. Apparatus as claimed in claim 30 or 31 wherein the ancillary device comprises an endoscope for transmitting visual information, and/or a needle for injecting a therapeutic agent into tissue.
33. Apparatus as claimed in any of claims 1 to 32 wherein the device is adapted for mounting to an instrument.
34. Apparatus as claimed in claim 33 wherein the device is adapted for mounting to a distal end of an instrument.
- 25 35. Apparatus as claimed in claim 33 or 34 wherein the instrument comprises an endoscope, a laparoscope, a thoracoscope or a ureteroscope.
36. Apparatus as claimed in any of claims 33 to 35 wherein the instrument comprises a catheter.

37. Apparatus as claimed in any of claims 1 to 36 wherein the apparatus comprises a connector lumen for connecting the active element and/or the sensor in communication with a controller.
- 5 38. Apparatus as claimed in claim 37 wherein the controller is configured to be located externally of a body.
- 10 39. Apparatus for carrying out prophylactic or treatment procedure on tissue substantially as hereinbefore described with reference to the accompanying drawings.
40. An instrument comprising an apparatus as claimed in any of claims 1 to 39.
- 15 41. An endoscope comprising an apparatus as claimed in any of claims 1 to 39.
42. A laparoscope comprising an apparatus as claimed in any of claims 1 to 39.
43. A thoracoscope comprising an apparatus as claimed in any of claims 1 to 39.
- 20 44. An ureteroscope comprising an apparatus as claimed in any of claims 1 to 39.
45. A catheter comprising an apparatus as claimed in any of claims 1 to 39
46. A method of prophylaxis or treatment of tissue comprising the steps of:
25 providing a device having a chamber and at least one active element within the chamber;
delivering the device to a site of interest;
30 drawing tissue into the chamber;

applying treatment to the tissue drawn into the chamber using the at least one active element within the chamber;

5 releasing the tissue from the chamber; and

withdrawing the device.

47. A method as claimed in claim 45 wherein the tissue is drawn into the chamber by applying a vacuum.
- 10
48. A method as claimed in claim 45 or 46 wherein the tissue is drawn towards the active element.
- 15
49. A method as claimed in claim 47 wherein the tissue is drawn into contact with the active element.
50. A method as claimed in any of claims 45 to 48 comprising the step of applying a stimulus to the tissue using the active element.
- 20
51. A method as claimed in any of claims 45 to 49 comprising the step of applying electrical energy to the tissue.
52. A method as claimed in any of claims 45 to 50 comprising the step of applying electromagnetic energy to the tissue.
- 25
53. A method as claimed in any of claims 45 to 51 comprising the step of applying nuclear energy to the tissue.

54. A method as claimed in any of claims 45 to 52 comprising the step of applying heat energy via microwave or alternative energy source to the tissue.
- 5 55. A method as claimed in any of claims 45 to 53 wherein the active element comprises a conductive element.
56. A method as claimed in any of claims 45 to 54 wherein the active element comprises an electrode.
- 10 57. A method as claimed in any of claims 45 to 55 wherein the active element comprises an optical element.
58. A method as claimed in any of claims 45 to 56 wherein the active element comprises a radiation source.
- 15 59. A method as claimed in any of claims 45 to 57 wherein the active element comprises an ultrasound source.
- 20 60. A method as claimed in any of claims 45 to 58 wherein the active element comprises an electrode and the treatment applied to the tissue is an electroporation treatment.
- 25 61. A method as claimed in any of claims 45 to 59 wherein the tissue is a diseased tissue.
62. A method as claimed in claim 60 wherein the tissue comprises a tumour.
- 30 63. A method as claimed in claim 61 wherein the tumour is oesophageal, colon, bladder, stomach, kidney, liver, pancreatic, fibrosarcoma, breast, prostate, glioma, lung, rectal, spleen, ovary, or melanoma type.

64. A method as claimed in any of claims 45 to 59 wherein the tissue is a healthy tissue.
- 5 65. A method as claimed in any of claims 45 to 63 comprising the step of carrying out a further procedure on the tissue.
66. A method as claimed in claim 64 wherein the further procedure is carried out before drawing tissue into the chamber.
- 10 67. A method as claimed in claim 64 or 65 wherein the further procedure is carried out after drawing tissue into the chamber.
68. A method as claimed in any of claims 64 to 66 wherein the further procedure is a treatment procedure.
- 15 69. A method as claimed in any of claims 64 to 67 wherein the further procedure is a visualisation procedure.
- 20 70. A method as claimed in any of claims 64 to 68 wherein the further procedure comprises a drug treatment procedure, or a diagnostic procedure.
71. A method as claimed in any of claims 45 to 69 wherein the method comprises the step of coupling one or more ancillary laparoscopic devices to the device.
- 25 72. A method as claimed in any preceding claim wherein the method comprises the step of injecting a therapeutic agent into the tissue.
73. A method as claimed in any of claims 45 to 71 wherein the device is mounted to or mountable to an instrument.

74. A method as claimed in claim 72 wherein the instrument is an endoscope, laparoscope, thoracoscope, or ureteroscope.
- 5 75. A method as claimed in claim 72 or 73 wherein the instrument comprises a catheter.
76. A method as claimed in any of claims 72 to 74 wherein the device is mounted to or mountable to a distal end of an instrument.
- 10 77. A method as claimed in any of claims 45 to 75 wherein the method comprises the step of monitoring the treatment procedure using a sensor.
78. A method as claimed in any of claims 45 to 76 wherein the method comprises the step of controlling the treatment procedure using a controller.
- 15 79. A method as claimed in any of claims 45 to 77 wherein the site of interest is a site on an external surface of a body.
80. A method as claimed in any of claims 45 to 78 wherein the site of interest is 20 an internal site within a body.
81. A method of prophylaxis or treatment of tissue substantially as hereinbefore described with reference to the accompanying drawings.










Fig. 1














Fig. 9







Fig. 10






Fig. 12




Fig. 13




Fig. 14(a)




Fig. 14(b)




Fig. 15





Fig. 16



INTERNATIONAL SEARCH REPORT

International Application No
PCT/IE2005/000030

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61N1/18 A61N5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61N A61K A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|--------------------------|
| X | US 2003/216730 A1 (BARRY ROBERT LAWRENCE ET AL) 20 November 2003 (2003-11-20) | 1-16, 20-38, 40-45 |
| Y | abstract; figures 7-11 | 17-19 |
| Y | US 4 587 958 A (NOGUCHI ET AL) 13 May 1986 (1986-05-13) abstract | 19 |
| Y | US 5 123 902 A (MUELLER ET AL) 23 June 1992 (1992-06-23) abstract | 17,18 |
| X | US 3 674 031 A (HANS-JOACHIM WEICHE) 4 July 1972 (1972-07-04) abstract; figures 1-3 | 1-16 |
| | | -/- |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 June 2005

Date of mailing of the international search report

29/06/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL – 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Edward, V

INTERNATIONAL SEARCH REPORTInternational Application No
PCT/IE2005/000030**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|-----------------------|
| A | US 4 130 112 A (FRAZER ET AL) 19 December 1978 (1978-12-19) abstract; figure 1 ----- | 1-38, 40-45 |
| A | US 5 277 696 A (HAGEN ET AL) 11 January 1994 (1994-01-11) the whole document ----- | 1-38, 40-45 |
| A | US 5 295 955 A (ROSEN ET AL) 22 March 1994 (1994-03-22) the whole document ----- | 1-38, 40-45 |

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Claims Nos.: 39, 46-81

Independent claim 46 relates to a method for treatment of the human or animal body by therapy (Rule 39.1(iv) PCT) due to the step of applying treatment to the tissue drawn into the chamber using at least one active element.

Continuation of Box II.2

Claims Nos.: 39,81

Claims 39 and 81 contain references to the description and the drawings. According to Rule 6.2(a) PCT, claims should not contain such references except where absolutely necessary, which is not the case here.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IE2005/000030

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 39, 46-81
because they relate to subject matter not required to be searched by this Authority, namely:
Independent claim 46 relates to a method for treatment of the human or animal body by therapy (Rule 39.1(iv) PCT) due to the step of applying treatment to the tissue drawn into the chamber using at least one active element.
2. Claims Nos.: 39, 81
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/IE2005/000030

| Patent document cited in search report | | Publication date | | Patent family member(s) | | Publication date |
|--|----|------------------|----|-------------------------|--|------------------|
| US 2003216730 | A1 | 20-11-2003 | AU | 2003213591 A1 | | 02-12-2003 |
| | | | CA | 2485483 A1 | | 27-11-2003 |
| | | | EP | 1539010 A2 | | 15-06-2005 |
| | | | WO | 03096886 A2 | | 27-11-2003 |
| US 4587958 | A | 13-05-1986 | WO | 8403828 A1 | | 11-10-1984 |
| | | | DE | 3378401 D1 | | 15-12-1988 |
| | | | DE | 139753 T1 | | 27-11-1986 |
| | | | EP | 0139753 A1 | | 08-05-1985 |
| US 5123902 | A | 23-06-1992 | DE | 3831141 A1 | | 22-03-1990 |
| | | | WO | 9002537 A1 | | 22-03-1990 |
| | | | EP | 0387324 A1 | | 19-09-1990 |
| | | | JP | 2983561 B2 | | 29-11-1999 |
| | | | JP | 3502537 T | | 13-06-1991 |
| | | | SU | 1837855 A3 | | 30-08-1993 |
| US 3674031 | A | 04-07-1972 | DE | 1916343 A1 | | 01-10-1970 |
| | | | CH | 522397 A | | 30-06-1972 |
| | | | FR | 2040113 A5 | | 15-01-1971 |
| | | | GB | 1271881 A | | 26-04-1972 |
| | | | JP | 52031674 B | | 16-08-1977 |
| US 4130112 | A | 19-12-1978 | | NONE | | |
| US 5277696 | A | 11-01-1994 | DE | 4138115 A1 | | 27-05-1993 |
| | | | DE | 59205754 D1 | | 25-04-1996 |
| | | | EP | 0543123 A1 | | 26-05-1993 |
| US 5295955 | A | 22-03-1994 | | NONE | | |

| | | | |
|----------------|---|---------|------------|
| 专利名称(译) | 用于预防或治疗组织的装置 | | |
| 公开(公告)号 | EP1727592A1 | 公开(公告)日 | 2006-12-06 |
| 申请号 | EP2005718820 | 申请日 | 2005-03-24 |
| [标]申请(专利权)人(译) | 愛爾蘭國立科克大學科克學院 | | |
| 申请(专利权)人(译) | 爱尔兰考克大学，国立大学，软木 | | |
| 当前申请(专利权)人(译) | 爱尔兰考克大学，国立大学，软木 | | |
| [标]发明人 | MORRISSEY ANTHONY SODEN DECLAN COLLINS CHRISTOPHER PIGGOTT JOHN 236 THE SWEEPSTAKES PRIOR DENTON THE COTTAGE WATSON ANDREW MCGEEHIN PETER | | |
| 发明人 | MORRISSEY, ANTHONY SODEN, DECLAN O'SULLIVAN, GERALD"CUAN BAOI" COLLINS, CHRISTOPHER DUNNE, COLUM 23 RICHVIEW PIGGOTT, JOHN 236 THE SWEEPSTAKES PRIOR, DENTON THE COTTAGE WATSON, ANDREW MCGEEHIN, PETER | | |
| IPC分类号 | A61N1/18 A61N5/00 A61B18/14 A61N1/32 A61N5/06 | | |
| CPC分类号 | C12M35/02 A61B18/1477 A61B18/1492 A61B2018/0016 A61B2018/00291 A61B2018/00482 A61B2018/00494 A61B2018/1425 A61B2018/143 A61B2218/002 A61N1/0424 A61N1/0476 A61N1/327 A61N5/0601 A61N5/062 | | |
| 优先权 | 2004011934 2004-05-27 GB 2004006709 2004-03-25 GB | | |
| 其他公开文献 | EP1727592B1 | | |
| 外部链接 | Espacenet | | |

摘要(译)

用于在组织上进行预防或治疗过程的装置(20)包括装置(21)，该装置(21)具有腔室(22)和至少一个活性元件，例如腔室(22)内的电极(23)。腔室(22)具有开口(26)，组织通过该开口被吸入腔室(22)中。用于将组织抽入腔室的装置可包括真空腔，腔室(22)中具有真空孔(25)。诸如电穿孔的处理可以应用于腔室(22)中的组织。

